Insmed company profile

INSM · NASDAQ · USD

Compare Insmed
$121.86Change from previous close: −0.83%Absolute change: −$1.02

Close · November 17, 2026

Company profile

Insmed has 1,664 employees and is headquartered in Bridgewater, United States.

Based in Bridgewater, New Jersey, and founded in 1988, Insmed focuses on treatments for rare and serious lung and other diseases. Its marketed product ARIKAYCE targets refractory nontuberculous mycobacterial lung infections. The pipeline includes brensocatib, a DPP1 inhibitor in phase 3 for bronchiectasis, an inhaled treprostinil palmitil formulation for pulmonary hypertension, and INS1201, a gene replacement therapy for Duchenne muscular dystrophy in phase 1. Research programs cover gene therapy and protein engineering. Its patients and markets are in the United States, Europe, Japan and other countries.

In the fiscal year ended December 2025, Insmed reported revenue of 606.4 million US dollars, up 66.7% from the previous year, and a net loss of 1.3 billion US dollars. The United States accounted for 74.7% of revenue and non-US markets for 25.3%. The company had 1,664 employees, and its headquarters are in Bridgewater.

Company facts

Industry
Biotechnology
Headquarters
700 US Highway 202/206, 08807, Bridgewater
Employees
1,664
Chief executive
William Lewis
Founded
1988
Fiscal year
January - December
Listing
INSM · NASDAQ
Currency
USD
ISIN
US4576693075
Website
insmed.com

Insmed and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
InsmedINSMUnited States$26.96B1,664-41.7%—
Roivant SciencesROIVUnited States$28.64B721-3,226.3%—
IncyteINCYUnited States$24.36B2,84432.2%61.0
Alnylam PharmaceuticalsALNYUnited States$22.11B2,50019.5%8.34
BioNTechBNTXUnited States$21.22B7,807-55.4%—
Revolution MedicinesRVMDUnited States$37.27B883-853.0%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Insmed with its competitors